Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Prothena Corporation PLC    PRTA   IE00B91XRN20

PROTHENA CORPORATION PLC (PRTA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
29.49(c) 29.74(c) 30.95(c) 32.11(c) 33.2(c) Last
500 302 486 605 363 711 571 672 433 233 Volume
+4.61% +0.85% +4.07% +3.75% +3.39% Change
More quotes
Financials ($)
Sales 2018 14,3 M
EBIT 2018 -229 M
Net income 2018 -230 M
Finance 2018 198 M
Yield 2018 -
Sales 2019 71,2 M
EBIT 2019 -182 M
Net income 2019 -182 M
Finance 2019 136 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 72,2x
EV / Sales2019 15,3x
Capitalization 1 229 M
More Financials
Company
Prothena Corp. Plc is a clinical stage biotechnology company, which engages in the discovery, development, and commercialization of novel antibodies.Its antibody-based product candidates target a number of potential indications including AL amyloidosis, Parkinson's disease and related... 
More about the company
Surperformance© ratings of Prothena Corporation PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTHENA CORPORATION PLC
02/14PROTHENA : Reports Fourth Quarter and Full Year 2017 Financial Results, and Prov..
GL
02/14PROTHENA CORPORATION PLC : Prothena Corp. Plc to Host Earnings Call
AC
02/07PROTHENA : to Participate in the Leerink Partners 7th Annual Global Healthcare C..
GL
02/02Prothena Announces Departure of Chief Medical Officer
GL
02/02PROTHENA : Announces Departure of Chief Medical Officer
GL
02/01PROTHENA : to Report Fourth Quarter and Full Year 2017 Financial Results and Hos..
GL
01/03PROTHENA : to Participate in the 36th Annual J.P. Morgan Healthcare Conference
GL
2017PROTHENA : to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Confe..
GL
2017PROTHENA : Highlights Breadth of Novel Pipeline at R&D Day
GL
2017Short seller Kerrisdale targets Woodford-backed Prothena
RE
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/17Prothena $PRTA Upgraded to “Sell” at BidaskClub  
02/16Oppenheimer Sets Prothena FY2022 Earnings Estimates at $2.41 EPS.  
02/16Jefferies Group Sets Prothena FY2019 Earnings Estimates at ($5.28) EPS.  
02/15Prothena $PRTA Reports Fourth Quarter and Full Year 2017 Financial Results, a.. 
02/15$AURX UNKNOWN OVERSOLD GEM, fell from $2 to .09 in a year will run back to $..
1
More tweets
Qtime:68
News from SeekingAlpha
02/16Prothena (PRTA) Presents At Leerink Partners 7th Annual Global Healthcare Con.. 
02/14Prothena's (PRTA) CEO Dr. Gene Kinney on Q4 2017 Results - Earnings Call Tran.. 
02/14Prothena beats by $0.24, misses on revenue 
02/13Notable earnings after Wednesday?s close 
02/05Midday Gainers / Losers (2/5/2018) 
Chart PROTHENA CORPORATION PLC
Duration : Period :
Prothena Corporation PLC Technical Analysis Chart | PRTA | IE00B91XRN20 | 4-Traders
Technical analysis trends PROTHENA CORPORATION PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 72,9 $
Spread / Average Target 127%
EPS Revisions
Managers
NameTitle
Gene G. Kinney President, Chief Executive Officer & Director
Lars G. Ekman Chairman
Tran B. Nguyen Chief Financial Officer
Wagner Zago Chief Scientific Officer
Richard T. Collier Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PROTHENA CORPORATION PLC-17.44%1 185
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055